Prof. Paolo Colombo, CEO of PlumeStars srl, has been invited to enter in the rExpert committee of the research project called AEROPERF. The project will take place in Liège, Belgium, subsidized by the Wallon Region. The Expert Committee included Prof. Nicolas Tsapis of Paris-Sud University and Marco Laackmann of Haro Hofliger.
Read more “Prof. Paolo Colombo invited in the Expert Committee of AEROPERF research project”
We are pleased to announce that the Controlled Release Society (CRS) has announced the election of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “PAOLO COLOMBO ELECTED INTO CONTROLLED RELEASE SOCIETY (CRS) COLLEGE OF FELLOWS”
We are pleased to announce that The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “Paolo Colombo Inducted into Medical and Biological Engineering Institute (AIMBE)”
Paolo Colombo, Emeritus of the University of Parma and CEO of PlumeStars, has been named among the top 60 industrial leaders in The Medicine Maker’s 2020 Power List 2020.
On 9th and 10 th December 2019, at the Department of Food and Drug of the University of Parma, the two days course “Quality by Design in Pharmaceutical Development. Theory and case studies”, will take place.
From 3rd to 6th of November, PlumStars will participate at AAPS 2019 AAPS, an annual Conference of the American Association of Pharmaceutical Scientists that will be held at Henry B. González Convention Center, San Antonio, TX, USA.
There will be pitching, demonstrations and great presentations, with take-aways for both investors and innovation driven organizations.
Prof. Paolo Colombo (PlumeStars CEO) will present two different speeches:
The first speech concerns Hyalcis exploits nanotechnology and advanced material research results to bring to market an innovative medical treatment of mesothelioma. The studies until now conducted revealed an interaction between the polymer hyaluronic acid and cisplatin that gave rise to a drug-polymer complex, lymphatically absorbed and blood distributed.
The uptake by pharmaceutical industry of the hyaluronic- cisplatin film technology studied by PlumeStars will assign a more effective cure against recurrences of this rare and very aggressive form of cancer that is difficult to diagnose and highly resistant to anticancer drugs.
Dr. Eride Quarta (PharmD; PhD Student, PlumeStars Research Leader) will present:
AAPS PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a niche meeting.
Five robust tracks covering all aspects of the pharmaceutical sciences, hundreds of exhibitors with dozens of additional learning opportunities, thousands of scientific posters featuring the latest, most innovative research in the field.
Also for this year, PlumeSTARS participated at the 59th AFI Symposium, the Italian Conference of the Industrial Pharmacists, held on 5, 6 and 7 June at the new Pala Congressi in Rimini.
The AFI Symposium is the important conference that for almost 60 years involves the interlocutors of the pharmaceutical sector at an international level, and this is why it is confirmed year by year an important moment of encounter and exchange between the protagonists of scientific research and the Companies. As for the update exam of great importance and considerable authority.
It consists of several scientific sessions, culminates with the Lectio magistralis and the Plenary Session and also includes spaces dedicated to:
PlumeSTARS presented, in a speech of Prof. Paolo Colombo (PlumeStars CEO), “Hyalcis: Hyaluronic-Cisplatin Film for Implant for Malignant Mesothelioma Recurrences”.
Hyalcis exploits nanotechnology and advanced material research results to bring to market an innovative medical treatment of mesothelioma. The studies until now conducted revealed an interaction between the polymer hyaluronic acid and cisplatin that gave rise to a drug-polymer complex, lymphatically absorbed and blood distributed.
The uptake by pharmaceutical industry of the hyaluronic- cisplatin film technology studied by PlumeStars will assign a more effective cure against recurrences of this rare and very aggressive form of cancer that is difficult to diagnose and highly resistant to anticancer drugs.
The film requires an advanced manufacturing process in order to guarantee its quality, in particular sterility.
Hyalcis combines a known active principle, cisplatin, with a polymeric material, hyaluronic acid, providing an innovative solution to post-surgery prevention of mesothelioma recurrences. The novel product has a demonstrable added value compared to the presently applied chemotherapy (IV or pleura surface washing) and radiotherapy treatments, since it allows a strict dose control and implantation easiness.
Hyalcis transfers the PlumeStars research results to the cancer therapy. PlumeStars technology could be transferred to treat other forms of cancer, thus multiplying the beneficial impact for society (e.g. ovarian cancer) and market.
The innovation provides clear societal benefits by more efficiently addressing a relevant illness form which full recovery is extremely rare.
PlumeSTARS srl, the start up at University of Parma, received a new financial funding within the Horizon 2020 program. In the last round of the EIC SME-Instrument Phase 1 – cut off of 13 February 2019 – 277 small and medium-sized enterprises from 25 EU countries have been selected for funding. PlumeSTARS is one of them.
PlumeSTARS got a contribution of 50,000 euros for preparing the Business Plan of its Orphan Medicine Hyalcis. The productis a Polymeric biodegradable film, loaded with cisplatin drug, the active substance for cancer treatment. The film, developed and tested in collaboration with the Department of Medicine & Surgery (Prof Paolo Carbognani) and Department Food & Drug (Prof. Fabio Sonvico) of the University of Parma, is proposed to be implanted in the thoracic surface after the removal of primary tumor in the pleural mesothelioma cancer. The product, already tested in animals, obtained the Orphan medicine designation and is on way for studies in human trials, with the goal of market authorization application.
Most of the selected SME-Instrument candidates are active in the ICT, health and engineering sectors: the beneficiary companies come from Spain (46), Switzerland (23) and France (22). 21 Italian companies are beneficiaries, including PlumeStars srl.
The SME- Instrument program is part of the European Innovation Council (EIC) pilot project, which supports high-level innovators, entrepreneurs, small businesses and scientists with funding opportunities and acceleration services.
On 12 and 13 April 2018, at the Department of Food and Drug of the University of Parma, the two days course “Quality by Design in Pharmaceutical Development” will take place. Theory and case studies”.
Saturday, January 13th the award ceremony of the Sant’Ilario Prize (2018 edition) was held at the Paganini Auditorium in Parma.
Prof. Paolo Colombo, Professor emeritus of the University of Parma and CEO of PlumeSTARS, has received the certificate of civic merit for the very high research activity in the field of pharmaceutical technology and for the fundamental contribution in the development of the most modern technologies and innovative products with the achievement of fundamental patents for the sector with recognition of numerous international awards and honors.
